Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807734 | 0.82 | GRM4 (0.37) | GRM4KDM4ELMNAPOLBAAK1 | |
| SCHEMBL28402863 | 0.78 | GRM4 (0.35) | GRM4KDM4ELMNAPOLBAAK1 | |
| SCHEMBL31728162 | 0.78 | SORD (0.36) | GRM4KDM4ELMNAPOLBAAK1 | |
| SCHEMBL21323650 | 0.78 | GRM4 (0.35) | GRM4KDM4ELMNAPOLBAAK1 | |
| SCHEMBL24359772 | 0.77 | GRM4 (0.34) | GRM4KDM4ELMNAPOLBAAK1 | |
| SCHEMBL23206269 | 0.76 | IDH1 (0.36) | GRM4KDM4ELMNAPOLBAAK1 | |
| SCHEMBL28223078 | 0.75 | POLB (0.40) | GRM4KDM4ELMNAPOLBAAK1 | |
| SCHEMBL25986793 | 0.74 | GRM4 (0.33) | GRM4KDM4ELMNA | |
| SCHEMBL21784412 | 0.72 | GRM4 (0.34) | GRM4KDM4ELMNAPOLBAAK1 | |
| SCHEMBL2751610 | 0.72 | SMN1; SMN2 (0.46) | GRM4KDM4ELMNAPOLBAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | GRM4 1120/4885KDM4E 3944/4885LMNA 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.